A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review.

A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review.

TiARA’s Professor Sheryl van Nunen, The Oncology Team at Royal North Shore Hospital, Sydney and GenesisCare have worked together on providing the evidence for making cetuximab safe for use in tick endemic regions by pre-treatment screening since late 2018. This paper endorses the approach prospectively as being highly effective in reducing the HSRs (Hypersensitivity Reactions) and validates using the cutoff of 0.10kUA/L.   

To read the article in full please click here